Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research
Editas Medicine Announces Enrollment of the First Pediatric
Amid The Turmoil Of 2020, This Company Was The First To Treat Patients With A Genome Editing Therapy
JPM 2022: Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022 | Fierce Biotech
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges - ScienceDirect
Frontiers | Prime Editing for Inherited Retinal Diseases | Genome Editing
Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials | British Journal of Ophthalmology
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 | Nature Medicine
Editas falls well short of Brilliance | Evaluate
Editas and Allergan Make Gene-Editing History With First Treatment of Blindness Drug | The Motley Fool
Yuancheng (Ryan) Lu on Twitter: "Editas has their gene editing AAV therapy application approved by FDA. Will start clinical trials. https://t.co/gD60RtSM6E" / Twitter
Editas Medicine | LinkedIn
Editas Wins FDA Approval for IND of CRISPR Treatment for LCA10
Editas Medicine: Plagued By Uncertainty, Awed By The Potential (NASDAQ:EDIT) | Seeking Alpha
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10 | Editas Medicine
Editas Medicine stock slumps 15%, chief scientific officer to retire, provides trial updates (NASDAQ:EDIT) | Seeking Alpha
Gene Editing
Editas Medicine (@editasmed) / Twitter
Editas Medicine doses first pediatric patient in clinical trial for LCA10
Delivery technologies for T cell gene editing: Applications in cancer immunotherapy - eBioMedicine
Gene Therapy for LCA10: The Brilliance Phase 1/2 Clinical Trial Of AGN-151587 (EDIT-101) Update
Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research: Molecular Therapy - Methods & Clinical Development
First CRISPR Trial to Edit DNA in Human Body | Thrivous®
